Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma
Phase 2 Terminated
23 enrolled
Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.
Phase 2 Terminated
3 enrolled 10 charts
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Phase 2 Terminated
31 enrolled 18 charts
Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults
Phase 2 Terminated
1 enrolled 7 charts
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
Phase 2 Terminated
1 enrolled 11 charts
Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML
Phase 2 Terminated
2 enrolled 8 charts
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
Phase 2 Terminated
20 enrolled 8 charts
Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer
Phase 2 Terminated
5 enrolled 10 charts
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Terminated
46 enrolled 18 charts
Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 2 Terminated
18 enrolled 18 charts
Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.
Phase 2 Terminated
2 enrolled
A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia
Phase 2 Terminated
3 enrolled 4 charts
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma
Phase 2 Terminated
20 enrolled 15 charts
Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma
Phase 2 Terminated
1 enrolled 2 charts
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD
Phase 2 Terminated
41 enrolled 13 charts
Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia
Phase 2 Terminated
37 enrolled 11 charts
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Phase 2 Terminated
342 enrolled 14 charts
Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL
Phase 2 Terminated
10 enrolled
Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
Phase 2 Terminated
16 enrolled 11 charts
Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow Transplantation
Phase 2 Terminated
3 enrolled 8 charts
Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)
Phase 2 Terminated
39 enrolled 10 charts
Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
Phase 2 Terminated
2 enrolled 8 charts
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
Phase 2 Terminated
45 enrolled 15 charts
Post Transplant Donor Lymphocyte Infusion
Phase 2 Terminated
57 enrolled 13 charts
Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
Phase 2 Terminated
32 enrolled
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
Phase 2 Terminated
442 enrolled 17 charts
Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)
Phase 2 Terminated
4 enrolled 5 charts
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
Phase 2 Terminated
24 enrolled 13 charts
Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab
Phase 2 Terminated
135 enrolled 17 charts
Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers
Phase 2 Terminated
15 enrolled 8 charts
Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen
Phase 2 Terminated
24 enrolled 17 charts
Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.
Phase 2 Terminated
16 enrolled 19 charts
Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer
Phase 2 Terminated
6 enrolled 9 charts
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
Phase 2 Terminated
24 enrolled 15 charts
Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer
Phase 2 Terminated
14 enrolled 9 charts
Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML
Phase 2 Terminated
2 enrolled 13 charts
Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)
Phase 2 Terminated
15 enrolled 12 charts
T-Cell Depleted Double UCB for Refractory AML
Phase 2 Terminated
3 enrolled 9 charts
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
Phase 2 Terminated
200 enrolled 11 charts
Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Phase 2 Terminated
6 enrolled 9 charts
Drosophila-generated CTL
Phase 2 Terminated
3 enrolled 8 charts
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
Phase 2 Terminated
13 enrolled 24 charts
A Phase II Study of Umbilical Cord Blood Transplantation
Phase 2 Terminated
7 enrolled 13 charts
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
Phase 2 Terminated
12 enrolled 12 charts
Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases
Phase 2 Terminated
1 enrolled 5 charts
High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant
Phase 2 Terminated
1 enrolled 6 charts
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Phase 2 Terminated
6 enrolled 5 charts
Methotrexate Followed by Fludarabine in Patients With T-Cell Large Granular Lymphocytic Leukemia
Phase 2 Terminated
12 enrolled
Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia
Phase 2 Terminated
21 enrolled
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
Phase 2 Terminated
16 enrolled 6 charts